InVivoSIM anti-human C5 (Eculizumab Biosimilar)
Catalog #SIM0011
Clone:
Eculizumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Eculizumab making it ideal for research use. This Eculizumab biosimilar reacts with human terminal complement component 5 (C5). C5 is a precursor protein synthesized in the liver. During complement activation, C5 is cleaved, producing two disulfide linked glycoproteins C5Ī± and C5Ī². C5Ī± is further cleaved by C5 convertase into C5a and C5Ī±’, the latter binds to C5Ī² to form C5b, which in turn sequentially recruits C6-C9 to form the membrane attack complex (MAC). MAC destroys pathogens by forming a lytic pore in their membrane. Eculizumab inhibits the cleavage of C5 to C5Ī± and C5Ī². Eculizumab is used for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Specifications
| Isotype | Human IgG4 |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | Human C5 |
| Reported Applications |
Inhibition of the activation of C5 Functional assays ELISA Immunoprecipitation |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from cell culture supernatant |
| Purification | Protein A |
| RRID | AB_2894732 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer